EUVIMEDEUVIMED entdecken
Crossref

Why India’s Chemical Industry Did Not Fully Realize Drug Discovery Potential After Independence

Rahul Hajare *

Journal of Women Health Care and Issues · 17.06.2026 · 09 (02) · 01-03

DOI: 10.31579/2642-9756/264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Women Health Care and Issues, online erschienen am 17.06.2026. Verfasst von Rahul Hajare *.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since gaining independence in 1947, India’s chemical and pharmaceutical sectors have evolved into global leaders in generic drug manufacturing; however, the country has not fully realized its potential in original drug discovery. This paper examines the historical, economic, and institutional factors that shaped this trajectory. A key policy milestone, the Indian Patents Act of 1970, fostered the growth of a robust generics industry by recognizing only process patents, thereby improving access to affordable medicines but limiting incentives for innovation. Post independence economic constraints, including limited capital availability and competing national priorities, further restricted investment in high-risk, long-term drug discovery. Additionally, weak academia–industry linkages and inadequate translational research frameworks hindered the conversion of scientific knowledge into viable drug candidates. Infrastructure deficits, fragmented research ecosystems, and regulatory uncertainties compounded these challenges, while talent migration reduced the domestic concentration of advanced research expertise. Indian pharmaceutical firms strategically prioritized generics, active pharmaceutical ingredients, and contract research services, benefiting from lower risk and faster returns but delaying engagement in novel drug development. Although the introduction of product patents in 2005 marked a shift toward innovation, the transition has been gradual due to late entry, high attrition rates, and financial risks associated with drug discovery. Despite these limitations, India is now undergoing a transformation driven by expanding biotechnology initiatives, increased government support, and improved global integration. With its strong foundation in synthetic chemistry and cost-efficient research capabilities, India is well-positioned to evolve into an innovation-driven pharmaceutical hub. This analysis underscores that India’s historical focus on accessibility over innovation, while socially impactful, delayed its emergence in global drug discovery—a gap that is now beginning to narrow.

Zitieren

APA

*, R. H. (2026). Why India’s Chemical Industry Did Not Fully Realize Drug Discovery Potential After Independence. Journal of Women Health Care and Issues, 09(02), 01-03. https://doi.org/10.31579/2642-9756/264

Vancouver

* RH. Why India’s Chemical Industry Did Not Fully Realize Drug Discovery Potential After Independence. Journal of Women Health Care and Issues. 2026;09(02):01-03. doi:10.31579/2642-9756/264

BibTeX
@article{2026,
  author = {*, Rahul Hajare},
  title = {Why India’s Chemical Industry Did Not Fully Realize Drug Discovery Potential After Independence},
  journal = {Journal of Women Health Care and Issues},
  year = {2026},
  volume = {09},
  number = {02},
  pages = {01--03},
  doi = {10.31579/2642-9756/264}
}
Kostenlos starten →